Pharmacoeconomic assessment of a drug, medical device, or other healthcare product can take on many forms and occur at multiple points in the development cycle. Cost-effectiveness analysis, a major component of pharmacoeconomic assessment, has traditionally occurred in the later phases of product development—either as a piggy-back to a phase III or pivotal clinical trial, or peri-authorization.
Join Medpace experts as they explore the application of pharmacoeconomic assessment throughout all phases of clinical trials as well as in observational studies, including registries and other post-marketing data collection. Discussion will cover topics including:
· How pharmacoeconomic assessment can be envisioned in the context of early phase product development, implemented, maintained to support product marketing, and used to inform future decision-making.
· Cost-effectiveness analysis at different phases in the product development cycle.
· Pharmacoeconomic assessment in the post-marketing context.
· Comparing and contrasting approaches for small/medium product developers relative to larger companies.
· Case studies on “real world” implementation.